SEC Form 4 · accession 0001209191-18-004394
Biohaven Pharmaceutical Holding Co Ltd. · BHVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Declan Doogan
Director
Period of report
Jan 16, 2018
Accepted (ET)
Jan 18, 2018 · 6:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001689813
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF2,F3 | Jan 16, 2018 | S | 37,033 | $26.59 | D | 1,487,027 | I | By The Declan Doogan 2014 Trust |
| Common SharesF4 | Jan 16, 2018 | S | 1,834 | $27.07 | D | 1,485,193 | I | By The Declan Doogan 2014 Trust |
| Common SharesF5 | Jan 17, 2018 | S | 23,726 | $26.19 | D | 1,461,467 | I | By The Declan Doogan 2014 Trust |
| Common SharesF6 | Jan 17, 2018 | S | 37,530 | $26.84 | D | 1,423,937 | I | By The Declan Doogan 2014 Trust |
| Common SharesF7 | Jan 18, 2018 | S | 4,546 | $26.71 | D | 1,419,391 | I | By The Declan Doogan 2014 Trust |
| Common SharesF8 | Jan 18, 2018 | S | 5,618 | $27.87 | D | 1,413,773 | I | By The Declan Doogan 2014 Trust |
| Common SharesF9 | Jan 18, 2018 | S | 17,671 | $28.71 | D | 1,396,102 | I | By The Declan Doogan 2014 Trust |
| Common Shares | Jan 18, 2018 | S | 100 | $29.22 | D | 1,396,002 | I | By The Declan Doogan 2014 Trust |
| Common SharesF10 | holding | — | — | — | 463,913 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F10Represents shares received directly by the Reporting Person in the Distribution.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 - $27.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- F3Includes 346,002 shares received by the Reporting Person from by Portage Biotech Inc. as a distribution in kind on a pro rata basis to its shareholders, effective January 15, 2017, which transaction was not required to be reported under SEC rules (the "Distribution").
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.03 - $27.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.64 - $26.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.
- F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.64 - $27.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.
- F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 - $26.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4.
- F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.20 - $28.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (8) to this Form 4.
- F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.21 - $29.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (9) to this Form 4.